TRIMTECH Therapeutics brings total seed round to $47 M with additional investment of $14 M to further develop TRIMTAC and TRIMGLUE targeted protein degradation portfolio

TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has raised an additional $14 million in…

Continue ReadingTRIMTECH Therapeutics brings total seed round to $47 M with additional investment of $14 M to further develop TRIMTAC and TRIMGLUE targeted protein degradation portfolio